Gilead disappoints, with 1st-qtr sales and earnings falling short of expectations
US biotech giant Gilead Sciences (Nasdaq: GILD) posted financial results for the first-quarter of 2016 late Thursday which missed analysts’ expectations, sending the firm’s stock down 6.25% to $90.95 in after-hours trading.
Total revenues were $7.8 billion in 2016 just 1% higher compared to $7.6 billion in 2015, and sharply missing analysts’ forecasts of $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
Net income was $3.6 billion or $2.53 per diluted share in 2016, down 16.3% compared to $4.3 billion or $2.76 per diluted share in 2015. Non-generally accepted accounting principles (GAAP) net income, which excludes acquisition-related, up-front collaboration, stock-based compensation and other expenses, was $4.3 billion or $3.03 per diluted share in 2016, down 6.5% compared to $4.6 billion or $2.94 per diluted share in 2015. Analysts expected earnings of about $3.15 a share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze